These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 25882602)

  • 1. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
    Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
    Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.
    Stavik B; Tinholt M; Sletten M; Skretting G; Sandset PM; Iversen N
    J Hematol Oncol; 2013 Jan; 6():5. PubMed ID: 23320987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study.
    Tinholt M; Viken MK; Dahm AE; Vollan HK; Sahlberg KK; Garred O; Børresen-Dale AL; Jacobsen AF; Kristensen V; Bukholm I; Kåresen R; Schlichting E; Skretting G; Lie BA; Sandset PM; Iversen N
    BMC Cancer; 2014 Nov; 14():845. PubMed ID: 25407022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer.
    Cui XY; Tinholt M; Stavik B; Dahm AE; Kanse S; Jin Y; Seidl S; Sahlberg KK; Iversen N; Skretting G; Sandset PM
    J Thromb Haemost; 2016 Feb; 14(2):387-96. PubMed ID: 26598923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shiga toxin downregulates tissue factor pathway inhibitor, modulating an increase in the expression of functional tissue factor on endothelium.
    Grabowski EF; Kushak RI; Liu B; Ingelfinger JR
    Thromb Res; 2013 Jun; 131(6):521-8. PubMed ID: 23642803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells.
    Tinholt M; Stavik B; Louch W; Carlson CR; Sletten M; Ruf W; Skretting G; Sandset PM; Iversen N
    PLoS One; 2015; 10(1):e0117404. PubMed ID: 25617766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.
    Abu Saadeh F; Norris L; O'Toole S; Mohamed BM; Langhe R; O'Leary J; Gleeson N
    Thromb Res; 2013 Nov; 132(5):627-34. PubMed ID: 24094893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism.
    Kwon A; Jo SH; Jo YA; Park JY; Kim M; Kang HJ; Kim HS; Cho HC; Lee YK
    Blood Coagul Fibrinolysis; 2014 Jul; 25(5):416-21. PubMed ID: 24448154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
    Curtit E; Pivot X; Henriques J; Paget-Bailly S; Fumoleau P; Rios M; Bonnefoi H; Bachelot T; Soulié P; Jouannaud C; Bourgeois H; Petit T; Tennevet I; Assouline D; Mathieu MC; Jacquin JP; Lavau-Denes S; Darut-Jouve A; Ferrero JM; Tarpin C; Lévy C; Delecroix V; Trillet-Lenoir V; Cojocarasu O; Meunier J; Pierga JY; Kerbrat P; Faure-Mercier C; Blanché H; Sahbatou M; Boland A; Bacq D; Besse C; Thomas G; Deleuze JF; Pauporté I; Romieu G; Cox DG
    Breast Cancer Res; 2017 Aug; 19(1):98. PubMed ID: 28830573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)α and TFPIβ.
    Maroney SA; Ellery PE; Wood JP; Ferrel JP; Martinez ND; Mast AE
    J Thromb Haemost; 2013 May; 11(5):911-8. PubMed ID: 23480518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
    Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
    Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells.
    Stavik B; Skretting G; Olstad OK; Sletten M; Dehli Vigeland M; Sandset PM; Iversen N
    PLoS One; 2012; 7(10):e47184. PubMed ID: 23071754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial cell-anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in mice.
    Wang J; Xiao J; Wen D; Wu X; Mao Z; Zhang J; Ma D
    Mol Carcinog; 2016 May; 55(5):882-96. PubMed ID: 25945811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of TFPI in human carotid stenosis.
    Stavik B; Holm S; Espada S; Iversen N; Sporsheim B; Bjerkeli V; Dahl TB; Sandset PM; Skjelland M; Espevik T; Skretting G; Halvorsen B
    Thromb Res; 2017 Jul; 155():31-37. PubMed ID: 28482260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of tissue factor and tissue factor pathway inhibitor in microparticles and subcellular fractions of normal and malignant prostate cell lines.
    Lwaleed BA; Lam L; Lasebai M; Cooper AJ
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):339-43. PubMed ID: 23524311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
    Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
    Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study.
    Tinholt M; Garred Ø; Borgen E; Beraki E; Schlichting E; Kristensen V; Sahlberg KK; Iversen N
    J Thromb Haemost; 2018 Jul; 16(7):1347-1356. PubMed ID: 29766637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association of single nucleotide polymorphisms of tissue factor and tissue factor pathway inhibitor with venous thromboembolism in patients with lung cancer].
    Zhang XL; Zhu J; Chen WH; Zhai ZG; Zhang YH
    Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(12):901-906. PubMed ID: 29665662
    [No Abstract]   [Full Text] [Related]  

  • 19. Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretions of chronic rhinosinusitis with nasal polyp.
    Shimizu S; Ogawa T; Takezawa K; Tojima I; Kouzaki H; Shimizu T
    Am J Rhinol Allergy; 2015; 29(4):235-42. PubMed ID: 26163243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.
    Pelkonen M; Luostari K; Tengström M; Ahonen H; Berdel B; Kataja V; Soini Y; Kosma VM; Mannermaa A
    BMC Cancer; 2015 May; 15():431. PubMed ID: 26014348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.